摘要
目的 :探讨肿瘤标志物Cyfra2 1 1在喉癌、喉咽癌早期诊断、病程进展、治疗监测中的作用。方法 :应用酶联免疫夹心抗体对 30例正常人、8例咽喉部良性肿瘤、32例喉癌、喉咽癌患者手术前后进行血清Cyfra2 1 1测定。结果 :喉癌、喉咽癌患者Cyfra2 1 1明显高于正常人及良性肿瘤患者 (P <0 0 1)。喉癌、喉咽癌术后半月Cyfra2 1 1明显下降 ,与正常人比较差异无显著性 ,Cyfra2 1 1与肿瘤TNM分期呈正相关。 结论 :Cyfra2 1 1作为一种新的肿瘤标志物 ,对喉癌和喉咽癌的病程进展、治疗监测和预后判断有重要临床价值。
Objective:To measure tumor marker Cyfra21 1 in patients with laryngeal,hypopharyngeal carcinoma and evaluate its value in early diagnosis,progress and treatment surveillance.Methods:Standardized sandwich enzyme linked immunosorbent assay was used to determine soluble Cyfra21 1 in 30 normal individuals,8 patients with benign tumor, and 32 patients with laryngeal or hypopharyngeal carcinoma.Results:Cyfra21 1 in patients with malignant tumor was significantly higher than that of patients with benign tumor(P<0.01) or normal individuals (P<0.01).Half a month after operation,the Cyfra21 1 contents were obviously decreased,the difference was not statistically significant compared with those of normal individuals.Cyfra21 1 levels were positively correlated with the tumor stages.Conclusion:Cyfra21 1 may be a new marker of laryngeal or hypopharyngeal carcinoma and may have important clinical value.
出处
《山东医科大学学报》
2000年第4期388-389,共2页
Acta Academiae Medicinae Shandong
关键词
喉肿瘤
咽肿瘤
角蛋白
Laryngeal neoplasms
Hypopharyngeal neoplasms
Keratin
